From the Department of Biomedicine and Prevention (V.D.R., J.S., R.F.), Interventional Neuroradiology Unit
From the Department of Biomedicine and Prevention (V.D.R., J.S., R.F.), Interventional Neuroradiology Unit.
AJNR Am J Neuroradiol. 2020 Nov;41(11):2088-2093. doi: 10.3174/ajnr.A6768. Epub 2020 Sep 24.
There is no consensus on the optimal antithrombotic medication for patients with acute ischemic stroke with anterior circulation tandem occlusions treated with emergent carotid stent placement and mechanical thrombectomy. The identification of factors influencing hemorrhagic risks can assist in creating appropriate therapeutic algorithms for such patients. This study aimed to investigate the impact of medical therapy on functional and safety outcomes in patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions.
A multicenter retrospective study on prospectively collected data was conducted. Only patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions of the anterior circulation were included. Univariate and multivariate analyses were performed on preprocedural, procedural, and postprocedural variables to assess factors influencing clinical outcome, symptomatic intracranial hemorrhage, stent patency, and successful intracranial vessel recanalization.
Ninety-five patients with acute ischemic stroke and tandem occlusions were included. Good clinical outcome (mRS ≤ 2) at 3 months was reached by 33 (39.3%) patients and was associated with baseline ASPECTS ≥ 8 (OR = 1.53; 95% CI, 1.16-2.00), ≤2 mechanical thrombectomy attempts (OR = 0.71; 95% CI, 0.55-0.99), and the absence of symptomatic intracranial hemorrhage (OR = 0.13; 95% CI , 0.03-0.51). Symptomatic intracranial hemorrhage was associated with a higher amount of intraprocedural heparin, ASPECTS ≤ 7, and ≥3 mechanical thrombectomy attempts. No relationships among types of acute antiplatelet regimen, intravenous thrombolysis, and symptomatic intracranial hemorrhage were observed. Patients receiving dual-antiplatelet therapy after hemorrhagic transformation had been ruled out on 24-hour CT were more likely to achieve functional independence and had a lower risk of symptomatic intracranial hemorrhage.
During carotid stent placement and mechanical thrombectomy for tandem occlusion treatment, higher intraprocedural heparin dosage (≥3000 IU) increased symptomatic intracranial hemorrhage risk when the initial ASPECTS was ≤7, and mechanical thrombectomy needs more than one passage for complete recanalization. Antiplatelets antiplatelets use were safe, and dual-antiaggregation therapy was related to better functional outcomes.
对于接受紧急颈动脉支架置入和机械血栓切除术治疗的急性前循环串联闭塞的缺血性脑卒中患者,目前对于最佳抗血栓药物治疗仍存在争议。确定影响出血风险的因素有助于为此类患者制定合适的治疗方案。本研究旨在探讨颈动脉支架置入和机械血栓切除术治疗前循环串联闭塞患者的药物治疗对功能和安全性结局的影响。
这是一项多中心前瞻性数据回顾性研究,仅纳入接受颈动脉支架置入和机械血栓切除术治疗的前循环串联闭塞患者。对术前、术中及术后的变量进行单因素和多因素分析,以评估影响临床结局、症状性颅内出血、支架通畅性和颅内血管再通成功的因素。
共纳入 95 例急性缺血性脑卒中伴串联闭塞患者。95 例患者中,3 个月时 mRS 评分≤2 的良好临床结局者有 33 例(39.3%),其基线 ASPECTS≥8(OR=1.53;95%CI,1.16-2.00)、机械血栓切除术尝试次数≤2(OR=0.71;95%CI,0.55-0.99)和无症状性颅内出血(OR=0.13;95%CI,0.03-0.51)是其影响因素。症状性颅内出血与术中肝素用量较多、ASPECTS≤7 和机械血栓切除术尝试次数≥3 相关。急性抗血小板方案类型、静脉溶栓与症状性颅内出血之间未见相关性。对于排除了 24 小时 CT 显示出血转化的接受双联抗血小板治疗的患者,更有可能实现功能独立性且症状性颅内出血风险较低。
在颈动脉支架置入和机械血栓切除术治疗串联闭塞时,对于初始 ASPECTS≤7 的患者,术中肝素剂量(≥3000IU)较高会增加症状性颅内出血的风险,而机械血栓切除术需要多次通过才能完全再通。抗血小板治疗是安全的,双联抗血小板治疗与更好的功能结局相关。